OncLive's 2015 Giants of Cancer Care Awards Announced Today

Published: Friday, May 29, 2015
CHICAGO, Ill. (May 29, 2015) – OncLive proudly announces the 2015 Giants of Cancer Care, a dozen medical pioneers recognized by a panel of eminent oncologists for landmark achievements that have changed the course of cancer treatment. Honorees will be introduced and celebrated TONIGHT at the 3rd Annual Giants of Cancer Care™ Award Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 S. Wabash Ave.

The 2015 honorees are being recognized for groundbreaking accomplishments, in fields including translational research, gene therapy, immuno-oncology and medical advocacy, that have helped save, prolong and improve lives of cancer patients. These elite oncologists, chosen from hundreds of nominees, join a world-class roster of clinicians and research scientists who have been honored by OncLive’s Giants of Cancer Care™ awards since the program began in 2013. The 2015 Giants program is sponsored by Novartis, Merck & Co., Inc., and Bayer Healthcare Pharmaceuticals, Inc.

“Our third annual Giants of Cancer Care ceremony celebrates those physicians and researchers who have devoted their time, talent, and resources to improving care for patients and families affected by cancer,” said Jack Lepping, vice chairman of Michael J. Hennessy Associates, Inc., parent company to OncLive/Giants of Cancer Care. “We applaud and appreciate their compassion and dedication to understanding this disease and developing life-changing treatments. By shining a spotlight on their work today, we not only honor their achievements but also hope to inspire more discoveries tomorrow.”

The 2015 Giants of Cancer Care are:

  • Breast Cancer – Gabriel N. Hortobagyi, MD, FACP, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Community Outreach/Education – Harold P. Freeman, MD, The Ralph Lauren Center for Cancer Care and Prevention, New York, N.Y.
  • Gastrointestinal Cancer – Robert J. Mayer, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass.
  • Genitourinary Cancer – Maha H. Hussain, MB, ChB, University of Michigan Comprehensive Cancer Center, Ann Arbor, Mich.
  • Gynecologic Malignancies – Robert C. Bast, Jr., MD, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Immuno-Oncology – Carl H. June, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
  • Lung Cancer – John Minna, MD, University of Texas, Southwestern Medical Center, Dallas, Texas.
  • Lymphoid Neoplasms – Emil J. Freireich, MD, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Melanoma/Skin – Antoni Ribas, MD, PhD, UCLA School of Medicine, Jonsson Comprehensive Cancer Center, Los Angeles, Calif.
  • Myeloid Neoplasms – Clara Bloomfield, MD, Ohio State University, Wexner Medical Center, Columbus, Ohio.
  • Scientific Advances – Robert A. Weinberg, PhD, Massachusetts Institute of Technology, Whitehead Institute, Boston, Mass.
  • Supportive/Palliative Care – Charles Loprinzi, MD, Mayo Clinic Cancer Center, Rochester, MN.
(A list of honorees with full bios is here http://giants.onclive.com/recipients/2015 and attached to this press release as a separate file.)

OncLive’s Giants of Cancer Care Awards reflect today’s new and dynamic world of cancer care and research. In 2015, more than 1.6 million new cases of cancer are expected to be diagnosed in the United States—and nearly 590,000 people will die from the disease, according to the National Cancer Institute. The most common cancers are projected to include breast cancer, lung cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, and leukemia. Research scientists and clinicians honored as Giants of Cancer Care are leading the battle against these devastating diseases.

The 2015 Giants of Cancer Care Selection Committee, chaired by Dr. Hope S. Rugo, an oncologist and hematologist specializing in breast cancer research and treatment, is an exclusive group of oncologists, clinicians and researchers. The nomination process was open to a national audience. The Selection Committee then considered each final nominee’s body of work, including clinical impact, significant contributions, and overall accomplishments in order to select 12 honorees from 8 tumor-specific categories and 4 specialty categories. For more information about the Selection Committee, visit http://giants.onclive.com/.

About OncLive

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x